Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig and local Oxford research communities. Ludwig Cancer Research Oxford celebrated its 10th Anniversary with a two-day Symposium held in September 2017, which was attended by members of the global Ludwig community, Ludwig Oxford branch and the Oxford cancer research community:


RS649 ORCRB_Exteriors4 286x100

ORCRB in Oxford Open Doors 2018

Posted 20/06/2018

   On Saturday 8th September 2018 12.30-3 pm, the Old Road Campus Research Building (ORCRB), housing the Ludwig Institute for Cancer Research, the Jenner Institute and the Structural Genomics Consortium (SGC) will open to the public as part of the Oxford Open Doors scheme run by the Oxford Preservation Trust. Learn about our cutting-edge research into cancer, infectious diseases and drug discovery through hands-on family-friendly activities, ...

Sarah De Val awarded Foundation Leducq programme grant

Posted 23/07/2018

  A team of six researchers, including Ludwig Oxford’s Sarah De Val and those from Germany and USA, have been awarded a prestigious Fondation Leducq Transatlantic Networks of Excellence Programme grant. These collaborative awards provide $6 million over five years for work centred on cardiovascular and neurovascular disease. Sarah’s team will characterise the transcription factor Klf2 and its role in blood vessel biology.

Understanding how RIPK2 inhibitors affect ubiquitin-mediated inflammatory signalling

Posted 23/07/2018

Activation of the bacteria-sensing NOD receptors triggers inflammatory signalling via Receptor-interacting protein kinase 2 (RIPK2). Since RIPK2 inhibitors targeting the ATP-binding pocket have been shown to block this signalling pathway, it was assumed that RIPK2 kinase activity was important for signal transmission. In this work published recently in EMBO Journal, Hrdinka, Schlicher and colleagues from Mads Gyrd-Hansen’s lab demonstrate that kinase activity is in fact dispensable for NOD signalling and that these RIPK2 inhibitors are instead preventing the binding of the ubiquitin ligase, XIAP, and the subsequent XIAP-mediated ubiquitination of RIPK2 necessary for downstream signalling. This work could have therapeutic implications since NOD signalling is associated with several chronic inflammatory conditions such as Crohn’s disease.

Recent publications

A TFEB nuclear export signal integrates amino acid supply and glucose availability. Nat Commun, 9 (1), pp. 2685. Article

PHD2 inactivation in Type I cells drives HIF-2α dependent multi-lineage hyperplasia and the formation of paraganglioma-like carotid bodies. J Physiol. Article

DNA Modifications: Naturally More Error Prone? Trends Genet, 34 (8), pp. 627-638. Article

Production of spliced peptides by the proteasome. Mol Immunol. Article

BEARscc determines robustness of single-cell clusters using simulated technical replicates. Nat Commun, 9 (1), pp. 1187. Article

Erratum to "DNA Replication and associated repair pathways are involved in the mutagenesis of methylated cytosine"[DNA Repair, 62 (2018) 1-7]. DNA Repair (Amst), 65, pp. 79. Article


Our researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Many of the research groups are interested the causes and consequences of differences among cells within a tumour and variability among different tumours. Find out more about the Ludwig research groups.



Ludwig Seminars take place in the NDMRB (TDI) Basement Seminar Room. All University members welcome.

Jelena Bezbradica Mirkovic: Studying innate immune responses to tissue injury (exact title tbc), 11/Oct/2018 11:00

Browse the Ludwig Seminar Series




abstract cell culture 600x150 160311n_0736